A phase 2, randomized, double-blind, placebo-controlled study to assess the tolerability and pharmacodynamic effects of CRD-740, a PDE9 inhibitor, in participants with chronic heart failure

Back

HFA Premium Access

A phase 2, randomized, double-blind, placebo-controlled study to assess the tolerability and pharmacodynamic effects of CRD-740, a PDE9 inhibitor, in participants with chronic heart failure

Session: Late breaking clinical trials: medical therapy

Topic: Pharmacotherapy

Speaker: Professor J. Udelson (Boston, US)

Event: Heart Failure 2024

Congress Presentation

Add to my library

About the speaker

Professor James E Udelson

Tufts Medical Center, Inc., Boston (United States of America)

7 presentations

0 follower

9 more presentations in this session

A phase 2b, randomised, double-blind, active controlled, multi centre study to evaluate the efficacy, safety and tolerability of oral AZD9977 and dapagliflozin treatment in patients with heart failure

Speaker: Professor C. Lam (Singapore, SG)

Access

Slides

Video

Discussant review - MIRACLE

Speaker: Professor M. Packer (Dallas, US)

Access

Slides

Video

Discussant review - CARDINAL HF

Speaker: Doctor A. Bohm (Bratislava, SK)

Access

Slides

Video

Readily available urinary sodium analysis in patients with acute decompensate Heart Failure

Speaker: Doctor E. Meekers (Genk, BE)

Access

Slides

Video

Discussant review - EASY-HF

Speaker: Doctor P. Pellicori (Glasgow, GB)

Access

Slides

Video

Access the full session

Late breaking clinical trials: medical therapy

Speakers: Professor J. Udelson, Professor C. Lam, Professor M. Packer, Doctor A. Bohm, Doctor E. Meekers...

Access

Video

About the event

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources